Bradwejn J - Search Results

1

Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.

Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H. Bradwejn J, et al. Am J Psychiatry. 1992 Jul;149(7):962-4. doi: 10.1176/ajp.149.7.962. Am J Psychiatry. 1992. PMID: 1609879

2

A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.

Bradwejn J, Koszycki D, Annable L, Couëtoux du Tertre A, Reines S, Karkanias C. Bradwejn J, et al. Biol Psychiatry. 1992 Nov 15;32(10):903-12. doi: 10.1016/0006-3223(92)90179-4. Biol Psychiatry. 1992. PMID: 1467375 Clinical Trial.

3

Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers.

Koszycki D, Bradwejn J, Bourin M. Koszycki D, et al. Among authors: bradwejn j. Eur Neuropsychopharmacol. 1991 May;1(2):137-41. doi: 10.1016/0924-977x(91)90715-7. Eur Neuropsychopharmacol. 1991. PMID: 1821703

4

Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder.

Bradwejn J, Koszycki D. Bradwejn J, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(2):237-9. doi: 10.1016/0278-5846(91)90086-g. Prog Neuropsychopharmacol Biol Psychiatry. 1991. PMID: 1908105

5

Dose ranging study of the effects of cholecystokinin in healthy volunteers.

Bradwejn J, Koszycki D, Bourin M. Bradwejn J, et al. J Psychiatry Neurosci. 1991 Jul;16(2):91-5. J Psychiatry Neurosci. 1991. PMID: 1911739 Free PMC article. Clinical Trial.

6

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.

Bradwejn J, Koszycki D, Shriqui C. Bradwejn J, et al. Arch Gen Psychiatry. 1991 Jul;48(7):603-10. doi: 10.1001/archpsyc.1991.01810310021005. Arch Gen Psychiatry. 1991. PMID: 2069490 Clinical Trial.

7

Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.

Bradwejn J, Koszycki D, Meterissian G. Bradwejn J, et al. Can J Psychiatry. 1990 Feb;35(1):83-5. doi: 10.1177/070674379003500115. Can J Psychiatry. 1990. PMID: 2180549 Clinical Trial.

8

Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.

Bradwejn J, Koszycki D, Couëtoux du Tertre A, Paradis M, Bourin M. Bradwejn J, et al. Psychopharmacology (Berl). 1994 Mar;114(2):257-61. doi: 10.1007/BF02244846. Psychopharmacology (Berl). 1994. PMID: 7838917 Clinical Trial.

9

The cholecystokinin hypothesis of anxiety and panic disorder.

Bradwejn J, Koszycki D. Bradwejn J, et al. Ann N Y Acad Sci. 1994 Mar 23;713:273-82. doi: 10.1111/j.1749-6632.1994.tb44075.x. Ann N Y Acad Sci. 1994. PMID: 8185169 Review. No abstract available.

10

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.

Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H. Bradwejn J, et al. Arch Gen Psychiatry. 1994 Jun;51(6):486-93. doi: 10.1001/archpsyc.1994.03950060050005. Arch Gen Psychiatry. 1994. PMID: 8192551 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters